ET Healthcare

What ET Healthcare does

ET Healthcare (星童医疗) is a privately held in-vitro diagnostics company that develops automated immunodiagnostics systems for hospital emergency departments, clinical core laboratories, and cardiac care units. Founded in 2008 by Dr. Hong Tan and Bob Zuk, the company is headquartered in Palo Alto, California with operating subsidiaries in Shanghai and Suzhou, China, and operates as a subsidiary of Access Medical Systems (AMS), which also owns life sciences instrument maker Gator Bio. ET Healthcare's flagship platform is the Pylon immunoassay system, built on proprietary Test-On-a-Probe (T.O.P) biosensor technology that loads multiple detection modalities onto a single probe. The platform is paired with a cyclic enhancement signal amplification method (50+ patents across US, China, Europe, and Japan) that achieves sub-pg/mL sensitivity in approximately 20 minutes, and a fluidics-free unitized test strip design that eliminates daily maintenance.

The product portfolio includes the Pylon 3D analyzer for near-patient testing, the higher-throughput Pylon IRIS (launched 2020), and the π (Pi) POCT device integration management platform that connects heterogeneous POCT devices with hospital information systems. A broad reagent menu covers cardiac markers (hs-TnI, hs-TnT, BNP, NT-proBNP), inflammation (PCT, IL-6, SAA, CRP), thrombosis (D-Dimer, FDP, TAT, PIC, TM, tPAIC), gastric function (PGI, PGII, G-17), reproductive hormones (β-hCG, AMH, FSH/LH/E2/P/T/PRL), and brain injury markers (S100β, MPO, Lp-PLA2, HFABP), all backed by 30+ NMPA registrations. The company has installed systems in over 1,000 hospitals across China, including Beijing Fuwai Hospital, Beijing Anzhen Hospital, Shanghai Xinhua Hospital, and Shandong Qilu Hospital, and has positioned itself as a leading domestic brand in the emergency/outpatient immunoassay segment where imported products historically held over 90% market share.

ET Healthcare makes money through a combined hardware sale and razor-and-blade reagents model. Pylon analyzers are placed in customer hospitals as capital equipment, while recurring revenue is generated through single-use unitized test strips sold per test across the expanding assay menu. The π POCT platform introduces a software/services component for multi-vendor device integration. Distribution is direct, via regional sales representatives in China supported by a Scientific Advisory Board that includes Dr. Allan S. Jaffe (Mayo Clinic) and Prof. Alan H.B. Wu (UCSF). The company has raised over $100M cumulatively, including a $105M+ 2021 round co-led by Hillhouse Capital and Sequoia Capital China with Kaiser Permanente as a notable strategic investor. ET Healthcare employs 501-1,000 people and does not publicly disclose revenue.

Name

ET Healthcare

Legal name

ET Healthcare, Inc.

Website

https://ethealthcare.com.cn

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

501–1,000 employees

Short description

ET Healthcare (星童医疗) is a Palo Alto and Shanghai-based in-vitro diagnostics company that develops the Pylon automated immunoassay platform — powered by proprietary Test-On-a-Probe biosensor and cyclic enhancement signal amplification technology — and sells instruments and unitized test strips to hospital emergency departments and clinical laboratories across China and selected global markets.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics

NAICS

Surgical and Medical Instrument Manufacturing (339112), Analytical Laboratory Instrument Manufacturing (334516)

SIC

Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL)

akta.pro secondary industries

Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK), Fall Detection, Safety & Emergency Response (PERS, Smart Home Health Sensors) (HLAHACAG)

Keywords

• Immunodiagnostics instruments
• Cardiac biomarker testing
• Point-of-care diagnostics
• Automated immunoassay systems
• In vitro diagnostics

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

1. Pylon Immunoassay Analyzers: Sale of Pylon automated immunoassay instruments (Pylon 3D, Pylon IRIS, Pylon 1) to hospitals and clinical laboratories. Instruments provide near-patient testing capabilities with no daily maintenance required.
2. Immunoassay Reagents and Test Strips: Unitized single-use test strips and reagents for various diagnostic tests including cardiac markers (hs-TnI, cTnI, BNP, NT-proBNP), inflammation markers (PCT, IL-6, CRP), hormones, and other analytes. Reagents are sold per test with single-dose packaging.
3. POCT Device Management Platform (π): Intelligent integration management platform for POCT devices that connects different brands of POCT equipment with hospital information systems. Enables remote management of devices, quality control, samples, reports and personnel.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

ET Healthcare develops and sells automated immunodiagnostics systems based on its proprietary Pylon platform. Core offerings are the Pylon 3D and Pylon IRIS immunoassay analyzers, a broad menu of unitized single-use test strip reagents covering cardiac, inflammation, thrombosis, gastric, fertility/hormone, brain injury, and atherosclerosis markers, and the π intelligent POCT device integration management platform. Products are sold to hospital clinical laboratories and emergency departments in China and internationally, with over 1,000 hospital installations.

Product overview

ET Healthcare (星童医疗) offers a unified product portfolio centered on the Pylon immunoassay platform powered by proprietary lab-on-a-tip technology. The core offerings include Pylon 3D and Pylon IRIS fully automated immunoassay instruments, which run a comprehensive menu of unitized test strip reagents covering cardiac markers (hs-TnI, hs-TnT, BNP, NT-proBNP), inflammation biomarkers (PCT, IL-6, SAA, CRP), thrombosis markers (D-Dimer, FDP, TAT, PIC, TM, tPAIC), gastric function (PGI, PGII, G-17), pregnancy/hormones (β-hCG, AMH, sex hormones), and brain/cardiovascular injury markers (S100β, MPO, Lp-PLA2, HFABP). The portfolio is complemented by the π intelligent POCT management platform for integrating multiple POCT devices with hospital information systems. The underlying technology includes Test-On-A-Probe (T.O.P) biosensor technology, SES (Single Epitope Sandwich) assay format, and cyclic signal amplification, all backed by 50+ global patents.

Differentiator

Problem solved

Functional benefit

Brands

• Pylon: Fully automated immunoassay system based on proprietary lab-on-a-tip technology for near-patient testing. Includes Pylon 3D and Pylon IRIS analyzers.
• Pylon IRIS
• π (Pi)
• Gator Bio

Products and services

• Pylon 3D Immunoassay Analyzer Fully automated immunoassay analyzer providing central-laboratory-grade performance in near-patient settings. Compatible with whole blood, serum, or plasma samples, supports micro-volume patient-friendly sample sizes, requires no daily maintenance, has no fluidics system for simple operation and low maintenance, and uses a compact space-saving form factor.
• Pylon IRIS Immunoassay Analyzer High-speed fully automated immunoassay system with multi-channel, high-throughput capability. Features AI vision automatic sample container type recognition, 9-minute turnaround from sample to result, batch processing capacity of 200+ tests per hour, 300 reagent positions with continuous random loading capability, and bidirectional LIS/HIS compatibility.
• π (Pi) POCT Device Integration Management Platform

Quantifiable outcome

• Sub-pg/mL sensitivity achieved in ~20 minutes assay time
• +5 more outcomes

Named customers9 records

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• Mayo Clinic - Dr. Allan S. JaffecoreStrategic or Co-development Partner · 1 January 2016Dr. Allan S. Jaffe, chair of Division of Clinical Core Laboratory Services at Mayo Clinic, serves on ET Healthcare's Scientific Advisory Board. He conducted China lecture tours in 2016-2017 to promote high-sensitivity cardiac troponin awareness and clinical application guidance.
• UCSF - Prof. Alan H.B. WucoreStrategic or Co-development Partner · 1 January 2016Prof. Alan H.B. Wu, Chief of Clinical Chemistry Laboratory at San Francisco General Hospital and UCSF professor, serves on ET Healthcare's Clinical Advisory Board. He conducted academic lectures in China on biomarker developments and mass spectrometry applications.
• HyTest Ltd.coreTechnology or Integration · 1 January 2011Licensed SES (Single Epitope Sandwich) technology for BNP detection from HyTest Ltd. SES is a trademark of HyTest Ltd. The technology addresses BNP molecular instability by using single epitope binding to stable ring structure.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Snibe (Shenzhen New Industries Biomedical Engineering): China's leading domestic chemiluminescence immunoassay company with broad hospital penetration. Competes head-to-head with ET Healthcare in Chinese hospital immunoassay and shares the same import-substitution playbook in cardiac, inflammation, and hormone test menus.
• Mindray: Largest Chinese IVD and patient monitoring company, with extensive immunoassay and blood cell analyzer portfolios sold globally. Overlaps with ET Healthcare in clinical chemistry/immunoassay and competes in Chinese hospital accounts, though with a much broader product portfolio.
• Maccura Biotechnology: Chinese IVD player offering clinical chemistry, immunoassay, and POCT platforms. Directly comparable as a domestic competitor targeting hospital laboratories with similar reagent menus and pricing strategies.
• QuidelOrtho: Specializes in POCT immunoassay including the Triage MeterPro for cardiac biomarkers (BNP, Troponin I, D-dimer). Closest direct POCT cardiac peer; comparable use case of rapid near-patient cardiac diagnostics in emergency settings.

Broad incumbents

• Roche Diagnostics: Global immunoassay leader with cobas and Elecsys platforms; hs-cTnI/T assays are the benchmark. Holds majority share in China's premium hospital segment and competes directly with ET Healthcare's emergency/POCT menu.
• Abbott Diagnostics: Global IVD and POCT leader behind the i-STAT and Alinity platforms, including ARCHITECT hs-cTnI. Sets the standard for near-patient cardiac diagnostics globally and competes with ET Healthcare both in China and in any US expansion.
• Siemens Healthineers: Operates the Atellica IM and ADVIA Centaur immunoassay platforms with comprehensive cardiac and sepsis menus. Major global competitor in central lab immunoassay with growing POCT footprint.
• Beckman Coulter Diagnostics: Global immunoassay leader behind Access and DxI platforms with broad cardiac and reproductive menus. Competes with ET Healthcare for hospital laboratory placements, particularly in Asia-Pacific and emerging markets.

Emerging players

• Response Biomedical: Cardiac POCT company focused on rapid troponin, BNP, and D-dimer testing for emergency departments. Smaller-scale peer with overlapping focus on near-patient cardiovascular biomarkers and similar target customers.

Others

• HyTest (part of Thermo Fisher Scientific): Cardiac biomarker antibody and reagent provider — also ET Healthcare's SES technology licensor for BNP detection. Indirectly comparable as an enabler of high-quality cardiac immunoassays across the industry.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Compliance33 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries3 records

Funding overview

Funding rounds6 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ET Healthcare